31 research outputs found
The study of the effectiveness of pathogenetic treatment of Β«dry eyeΒ» Syndrome
In research we investigated the effectiveness ot therapy associated with transient corneal conjunctival xerosis: the patients after surgery a Lasik, includes traditional complex therapy with antibiotic, steroid anti-inflammatory and agents for substitution therapy and combinative therapy with immunomodlators and antioxidant agents. The comparative analysis of clinical symptoms, results of visiometry, data of laboratory examination, indicators of production of lacrimal liquid, factor of local immune protection at application of the medicines containing immunomodulators and antioxidants in the form of eye drops in the complex scheme of therapy of corneal-conjunctival xerosis was made. Pharmaceutical interaction was excluded by observing time intervals. The proposed scheme increased the secretion of lacrimal fluid and the factor of local immune protection of the epithelium of the mucous eye of patients. In this case, there was a decrease in clinical symptoms of the disease, a decrease in the sensitivity of the cornea to external factors, a positive dynamics of laboratory parameters, a decrease in the side effects of steroid anti-inflammatory drugs and antibacterial agents, which are expressed in increasing local immunity and improving the quality of life of patients.Π ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π»Π°ΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΡ
Π΅ΠΌ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΡΠ°Π½Π·ΠΈΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠ³ΠΎΠ²ΠΈΡΠ½ΠΎ-ΠΊΠΎΠ½ΡΡΠ½ΠΊΡΠΈΠ²Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΡΠ΅ΡΠΎΠ·Π°, Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΏΠΎΡΠ»Π΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠΉ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ ΠΠΠΠΠ, Π²ΠΊΠ»ΡΡΠ°ΡΡΠΈΡ
ΡΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΡΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ Π°Π½ΡΠΈΠ±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ
, ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΡΡ
ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΈ Π·Π°ΠΌΠ΅ΡΡΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ² ΠΈ ΡΡ
Π΅ΠΌ Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠΌΠΎΠ΄ΡΠ»ΡΡΡΡΡΠΈΠΌΠΈ ΡΡΠ΅Π΄ΡΡΠ²Π°ΠΌΠΈ. ΠΡΠ» ΠΏΡΠΎΠΈΠ·Π²Π΅Π΄Π΅Π½ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ², ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π²ΠΈΠ·ΠΈΠΎΠΌΠ΅ΡΡΠΈΠΈ, Π΄Π°Π½Π½ΡΡ
Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠΈ ΡΠ»Π΅Π·Π½ΠΎΠΉ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠΈ, ΡΠ°ΠΊΡΠΎΡΠ° ΠΌΠ΅ΡΡΠ½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ Π·Π°ΡΠΈΡΡ ΠΏΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ², ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΡ
ΠΈΠΌΠΌΡΠ½ΠΎΠΌΠΎΠ΄ΡΠ»ΡΡΠΎΡΡ Π² ΡΠΎΡΠΌΠ΅ Π³Π»Π°Π·Π½ΡΡ
ΠΊΠ°ΠΏΠ΅Π»Ρ Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΡΡ
Π΅ΠΌΠ΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠΎΠ³ΠΎΠ²ΠΈΡΠ½ΠΎ-ΠΊΠΎΠ½ΡΡΠ½ΠΊΡΠΈΠ²Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΡΠ΅ΡΠΎΠ·Π°. Π€Π°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΠΈΡΠΊΠ»ΡΡΠ°Π»ΠΎΡΡ ΠΏΡΡΠ΅ΠΌ ΡΠΎΠ±Π»ΡΠ΄Π΅Π½ΠΈΡ Π²ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
ΠΈΠ½ΡΠ΅ΡΠ²Π°Π»ΠΎΠ². ΠΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½Π½Π°Ρ ΡΡ
Π΅ΠΌΠ° ΠΏΠΎΠ²ΡΡΠ°Π»Π° ΡΠ΅ΠΊΡΠ΅ΡΠΈΡ ΡΠ»Π΅Π·Π½ΠΎΠΉ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠΈ ΠΈ ΡΠ°ΠΊΡΠΎΡ ΠΌΠ΅ΡΡΠ½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ Π·Π°ΡΠΈΡΡ ΡΠΏΠΈΡΠ΅Π»ΠΈΡ ΡΠ»ΠΈΠ·ΠΈΡΡΠΎΠΉ Π³Π»Π°Π·Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΡΠΈ ΡΡΠΎΠΌ ΠΏΡΠΎΠΈΡΡ
ΠΎΠ΄ΠΈΠ»ΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ² Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΡΠΎΠ³ΠΎΠ²ΠΈΡΡ ΠΊ Π²Π½Π΅ΡΠ½ΠΈΠΌ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌ, ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½Π°Ρ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ° Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ, ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎΠ±ΠΎΡΠ½ΡΡ
ΡΡΡΠ΅ΠΊΡΠΎΠ² ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΡΡ
ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ² ΠΈ Π°Π½ΡΠΈΠ±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ², Π²ΡΡΠ°ΠΆΠ°ΡΡΠΈΡ
ΡΡ Π² ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠΈ ΠΌΠ΅ΡΡΠ½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ° ΠΈ ΡΠ»ΡΡΡΠ΅Π½ΠΈΡ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²
Evaluation of the safety and the rational use of schemes of combination therapy of "dry eye" syndrome
A comparative study of the efficacy and safety of therapy of transient corneal-conjunctival xerosis (CCX) was conducted. Patients suffering from CCX received topically in the form of eye drops immunomodulators and antioxidants accompanied by traditional therapy, including a glucocorticosteroid, an aminoglycoside group antibiotic and substitution therapy with a preparation containing dextran-70 and hypromelase. The chemical interaction between the components of the schemes was excluded, since the time intervals for instillation of the drugs were respected. Based on the dynamics of laboratory data, instrumental examination (results of visiometry) and clinical manifestations of CCX, conclusions were drawn about the rationality and safety of the therapy used. Analysis of the production of tear fluid, the stability of the tear film, the results of optical coherence tomography (OCT) revealed the clinical and pharmacological advantage of the scheme containing the immunomodulator and antioxidant.ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΡΠ°Π½Π·ΠΈΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠ³ΠΎΠ²ΠΈΡΠ½ΠΎ-ΠΊΠΎΠ½ΡΡΠ½ΠΊΡΠΈΠ²Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΡΠ΅ΡΠΎΠ·Π° (Π ΠΠ). ΠΠ°ΡΠΈΠ΅Π½ΡΡ, ΡΡΡΠ°Π΄Π°ΡΡΠΈΠ΅ Π ΠΠ ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ ΠΌΠ΅ΡΡΠ½ΠΎ Π² ΡΠΎΡΠΌΠ΅ Π³Π»Π°Π·Π½ΡΡ
ΠΊΠ°ΠΏΠ΅Π»Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠΌΠΎΠ΄ΡΠ»ΡΡΠΎΡΡ ΠΈ Π°Π½ΡΠΈΠΎΠΊΡΠΈΠ΄Π°Π½ΡΡ Π² ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π΅Π½ΠΈΠΈ ΡΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, Π²ΠΊΠ»ΡΡΠ°ΡΡΡΡ Π³Π»ΡΠΊΠΎΠΊΠΎΡΡΠΈΠΊΠΎΡΡΠ΅ΡΠΎΠΈΠ΄, Π°Π½ΡΠΈΠ±ΠΈΠΎΡΠΈΠΊ Π³ΡΡΠΏΠΏΡ Π°ΠΌΠΈΠ½ΠΎΠ³Π»ΠΈΠΊΠΎΠ·ΠΈΠ΄ΠΎΠ² ΠΈ Π·Π°ΠΌΠ΅ΡΡΠΈΡΠ΅Π»ΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ, ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΠΌ Π΄Π΅ΠΊΡΡΡΠ°Π½-70 ΠΈ Π³ΠΈΠΏΡΠΎΠΌΠ΅Π»Π°Π·Ρ. Π₯ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΠΌΠ΅ΠΆΠ΄Ρ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ°ΠΌΠΈ ΡΡ
Π΅ΠΌ ΠΈΡΠΊΠ»ΡΡΠ°Π»ΠΎΡΡ, ΡΠ°ΠΊ ΠΊΠ°ΠΊ ΡΠΎΠ±Π»ΡΠ΄Π°Π»ΠΈΡΡ ΠΈΠ½ΡΠ΅ΡΠ²Π°Π»Ρ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ ΠΈΠ½ΡΡΠΈΠ»Π»ΡΡΠΈΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ². ΠΠ° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
Π΄Π°Π½Π½ΡΡ
, ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ Π ΠΠ Π±ΡΠ»ΠΈ ΡΠ΄Π΅Π»Π°Π½Ρ Π²ΡΠ²ΠΎΠ΄Ρ ΠΎ ΡΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΠΌΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΠ½Π°Π»ΠΈΠ· ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠΈ ΡΠ»Π΅Π·Π½ΠΎΠΉ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠΈ, ΡΡΠ°Π±ΠΈΠ»ΡΠ½ΠΎΡΡΠΈ ΡΠ»Π΅Π·Π½ΠΎΠΉ ΠΏΠ»Π΅Π½ΠΊΠΈ, ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΎΠΏΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠΎΠ³Π΅ΡΠ΅Π½ΡΠ½ΠΎΠΉ ΡΠΎΠΌΠΎΠ³ΡΠ°ΡΠΈΠΈ (ΠΠΠ’) Π²ΡΡΠ²ΠΈΠ» ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎΒΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²ΠΎ ΡΡ
Π΅ΠΌΡ, ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠ΅ΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΠΌΠΎΠ΄ΡΠ»ΡΡΠΎΡ ΠΈ Π°Π½ΡΠΈΠΎΠΊΡΠΈΠ΄Π°Π½Ρ
Optimization and pharmacoeconomic aspects of treatment of the syndrome of "dry eye"
The results of pharmacoeconomic analysis of complex therapy regimens for transient corneal-conjunctival xerosis "Dry eye" (DES) syndrome are presented in the study. The advantage of the scheme with the use of an immunomodulator, an antioxidant, stimulant of regeneration with standard DES therapy in comparison with the standard treatment regimen for pharmacoeconomic indicators, the dynamics of clinical symptoms, and clinical efficacy was revealed.Π Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΠ΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ ΡΠ°ΡΠΌΠ°ΠΊΠΎΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΡ
Π΅ΠΌ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° Β«ΡΡΡ
ΠΎΠ³ΠΎ Π³Π»Π°Π·Π°Β» Π‘Π‘Π. ΠΡΡΠ²Π»Π΅Π½Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈ ΡΠ°ΡΠΌΠ°ΠΊΠΎΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π° ΡΡ
Π΅ΠΌΡ Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΠΌΠΎΠ΄ΡΠ»ΡΡΠΎΡΠ°, Π°Π½ΡΠΈΠΎΠΊΡΠΈΠ΄Π°Π½ΡΠ° ΠΈ ΡΡΠΈΠΌΡΠ»ΡΡΠΎΡΠ° ΡΠ΅Π³Π΅Π½Π΅ΡΠ°ΡΠΈΠΈ Π² ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π΅Π½ΠΈΠΈ ΠΊ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π‘Π‘Π ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΡΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΡ
Π΅ΠΌΠΎΠΉ Π»Π΅ΡΠ΅Π½ΠΈΡ
Substantiation of complex therapy "dry eye" syndrome according to pharmacoeconomic analysis and experimental model
This study researched the clinical symptoms of postoperative βdry eye syndrome" and laboratory parameters: total production of the tear fluid, the rate of tear film stability, indicators of local immune resistance in patients with dry eye syndrome and experimental animal models (rabbits) under general anesthesia in the combined use of the derinat, emoxipine stillavit and accompanied by traditional therapy of dry eye syndrome. The research revealed, that this scheme increases lacrimal glands function, tear film stability, as well as enhances the local immune defense in these patients in the experiment. Pharmacoeconomic analysis revealed greater efficiency schemes with derinat, emoxipine and solcoseryl.Π Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ ΡΠΈΠΌΠΏΡΠΎΠΌΡ ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° Β«ΡΡΡ
ΠΎΠ³ΠΎ Π³Π»Π°Π·Π°Β» (Π‘Π‘Π): ΡΡΠΌΠΌΠ°ΡΠ½Π°Ρ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡ ΡΠ»Π΅Π·Π½ΠΎΠΉ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠΈ, ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΌΠ΅ΡΡΠ½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΈ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΌΠΎΠ΄Π΅Π»ΠΈ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
(ΠΊΡΠΎΠ»ΠΈΠΊΠΎΠ²) Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΠΎΠ±ΡΠ΅ΠΉ Π°Π½Π΅ΡΡΠ΅Π·ΠΈΠΈ ΠΏΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ Π΄Π΅ΡΠΈΠ½Π°ΡΠ°, ΡΠΌΠΎΠΊΡΠΈΠΏΠΈΠ½Π° ΠΈ ΡΠΎΠ»ΠΊΠΎΡΠ΅ΡΠΈΠ»Π° Π² ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π΅Π½ΠΈΠΈ ΡΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π‘Π‘Π. ΠΡΡΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΡΠΊΠ°Π·Π°Π½Π½Π°Ρ ΡΡ
Π΅ΠΌΠ° ΠΏΠΎΠ²ΡΡΠ°Π΅Ρ ΡΡΠ½ΠΊΡΠΈΡ ΡΠ»Π΅Π·ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΠΌΠ΅ΡΡΠ½ΡΡ ΠΈΠΌΠΌΡΠ½Π½ΡΡ Π·Π°ΡΠΈΡΡ Ρ Π΄Π°Π½Π½ΠΎΠΉ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΈ Π² ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ΅. ΠΡΠΈ ΡΠ°ΡΠΌΠ°ΠΊΠΎΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠΌ Π°Π½Π°Π»ΠΈΠ·Π΅ ΠΎΡΠΌΠ΅ΡΠ΅Π½Π° Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ°Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΡ
Π΅ΠΌΡ Ρ Π΄Π΅ΡΠΈΠ½Π°ΡΠΎΠΌ, ΡΠΌΠΎΠΊΡΠΈΠΏΠΈΠ½ΠΎΠΌ ΠΈ ΡΠΎΠ»ΠΊΠΎΡΠ΅ΡΠΈΠ»ΠΎΠΌ
Optimization of therapy of corneal conjunctival xerosis and evaluation of pharmacoeconomic efficiency
In this study, the analysis of transient corneal-conjunctival xerosis (CCX) therapy, clinical manifestations and indices of local immune resistance and lacrimal gland function were included in the inclusion of pro-activ and actipol in CCX complex therapy. It was found that this scheme increases the function of tear formation and favorably affects local immune defense (the factor of nonΒspecific immune resistance and the pro-inflammatory cytokine IL-1 b) in this category of patients. With the pharmacoeconomic analysis performed, taking into account the frequency of recurrence and the duration of remission, greater efficacy was shown in the use of immunomodulatory therapy.Π Π΄Π°Π½Π½ΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΡΠΎΠΈΠ·Π²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΡΠ°Π½Π·ΠΈΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠ³ΠΎΠ²ΠΈΡΠ½ΠΎ-ΠΊΠΎΠ½ΡΡΠ½ΠΊΡΠΈΠ²Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΡΠ΅ΡΠΎΠ·Π° (Π ΠΠ), ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ ΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΌΠ΅ΡΡΠ½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΈ ΡΠ»Π΅Π·Π½ΡΡ
ΠΆΠ΅Π»Π΅Π· ΠΏΡΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΠΈ Β«ΠΡΠΎ-Π°ΠΊΡΠΈΠ²Π°Β» ΠΈ Π°ΠΊΡΠΈΠΏΠΎΠ»Π° Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π ΠΠ. ΠΡΡΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΡΠΊΠ°Π·Π°Π½Π½Π°Ρ ΡΡ
Π΅ΠΌΠ° ΠΏΠΎΠ²ΡΡΠ°Π΅Ρ ΡΡΠ½ΠΊΡΠΈΡ ΡΠ»Π΅Π·ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΠΈ Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΠΎ Π²Π»ΠΈΡΠ΅Ρ Π½Π° ΠΌΠ΅ΡΡΠ½ΡΡ ΠΈΠΌΠΌΡΠ½Π½ΡΡ Π·Π°ΡΠΈΡΡ (ΡΠ°ΠΊΡΠΎΡ Π½Π΅ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ ΠΈ ΠΏΡΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΠΈΡΠΎΠΊΠΈΠ½ IL-1b) Ρ Π΄Π°Π½Π½ΠΎΠΉ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΡΠΈ ΠΏΡΠΎΠΈΠ·Π²Π΅Π΄Π΅Π½Π½ΠΎΠΌ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ·ΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠΌ Π°Π½Π°Π»ΠΈΠ·Π΅ Ρ ΡΡΠ΅ΡΠΎΠΌ ΡΠ°ΡΡΠΎΡΡ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΡΠ΅ΠΌΠΈΡΡΠΈΠΈ Π²ΡΡΠ²Π»Π΅Π½Π° Π±ΠΎΠ»ΡΡΠ°Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠΌΠΎΠ΄ΡΠ»ΠΈΡΡΡΡΠ΅ΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ
Evaluation of the safety and the rational use of schemes of combination therapy of "dry eye" syndrome
The study focused on the pathogenetic orientation of the therapy of transient Β« dry eyeΒ» syndrome (corneal-conjunctival xerosis (Π‘Π‘Π₯)) in patients after surgery for laser vision correction. Patients suffering from postoperative Π‘Π‘Π₯ received, in the form of instillation of eye drops, preparations with an immunomodulatory effect, a para-aminobenzoic acid derivative interferon inducer in addition to the standard combination therapy regimen, including tobramycin, dexamethasone, and a preparation containing dextran-70 and hypromelase. To exclude chemical interaction, the time intervals for drug instillation were observed. When analyzing the dynamics of the course of CCX, the data of clinical and laboratory indicators of lacrimation, the results of instrumental examination, indicators of the course of the inflammatory process IL4 in the anterior chamber of the eye were taken into account. Based on a comparative analysis, a conclusion was made about the clinical and pharmacological advantage of complex therapy with the use of immunomodulatory agent.Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ Π±ΡΠ» ΡΠ΄Π΅Π»Π°Π½ Π°ΠΊΡΠ΅Π½Ρ Π½Π° ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΡΡ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΠΎΡΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΡΠ°Π½Π·ΠΈΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° Β«ΡΡΡ
ΠΎΠ³ΠΎ Π³Π»Π°Π·Π°Β» (Π‘Π‘Π) Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΏΠΎΡΠ»Π΅ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ ΠΏΠΎ Π»Π°Π·Π΅ΡΠ½ΠΎΠΉ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΠΈ Π·ΡΠ΅Π½ΠΈΡ. ΠΠ°ΡΠΈΠ΅Π½ΡΡ, ΡΡΡΠ°Π΄Π°ΡΡΠΈΠ΅ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΠΌ Π‘Π‘Π ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ Π² Π²ΠΈΠ΄Π΅ ΠΈΠ½ΡΡΠΈΠ»Π»ΡΡΠΈΠΉ Π³Π»Π°Π·Π½ΡΡ
ΠΊΠ°ΠΏΠ΅Π»Ρ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠΌΠΎΠ΄ΡΠ»ΠΈΡΡΡΡΠΈΠΌ ΡΡΡΠ΅ΠΊΡΠΎΠΌ, ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΠΎΠ΅ ΠΏΠ°ΡΠ°Π°ΠΌΠΈΠ½ΠΎΠ±Π΅Π½Π·ΠΎΠΉΠ½ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ, ΠΈΠ½Π΄ΡΠΊΡΠΎΡ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Π°, Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΊ ΡΡ
Π΅ΠΌΠ΅ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠΉ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, Π²ΠΊΠ»ΡΡΠ°ΡΡΠ΅ΠΉ ΡΠΎΠ±ΡΠ°ΠΌΠΈΡΠΈΠ½, Π΄Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½ ΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ, ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΠΉ Π΄Π΅ΠΊΡΡΡΠ°Π½-70 ΠΈ Π³ΠΈΠΏΡΠΎΠΌΠ΅Π»Π°Π·Ρ. Π΄Π»Ρ ΠΈΡΠΊΠ»ΡΡΠ΅Π½ΠΈΡ Ρ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡ ΡΠΎΠ±Π»ΡΠ΄Π°Π»ΠΈΡΡ Π²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΈΠ½ΡΠ΅ΡΠ²Π°Π»Ρ ΠΈΠ½ΡΡΠΈΠ»Π»ΡΡΠΈΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ². ΠΡΠΈ Π°Π½Π°Π»ΠΈΠ·Π΅ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π‘Π‘Π ΡΡΠΈΡΡΠ²Π°Π»ΠΈΡΡ Π΄Π°Π½Π½ΡΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΡΠ»Π΅Π·ΠΎΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡ, ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° Π² ΠΏΠ΅ΡΠ΅Π΄Π½Π΅ΠΉ ΠΊΠ°ΠΌΠ΅ΡΠ΅ Π³Π»Π°Π·Π°, IL 4. ΠΠ° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° Π±ΡΠ»ΠΎ ΡΠ΄Π΅Π»Π°Π½ΠΎ Π·Π°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΠΌΠΎΠ΄ΡΠ»ΠΈΡΡΡΡΠ΅Π³ΠΎ ΡΡΠ΅Π΄ΡΡΠ²Π°
Analysis of pharmacoeconomic parameters of therapy of corneal conjunctival xerosis with the use of immunomodulator and antioxidant
The results of pharmacoeconomic analysis of complex therapy regimens for transient corneal-conjunctival xerosis (CCX) are presented in the study. The advantage of the scheme with the use of an immunomodulator and an antioxidant with standard CCX therapy in comparison with the standard treatment regimen for pharmacoeconomic indicators, the dynamics of clinical symptoms, and clinical efficacy was revealed.Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ°ΡΠΌΠ°ΠΊΠΎΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΡΡ
Π΅ΠΌ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΡΠ°Π½Π·ΠΈΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠ³ΠΎΠ²ΠΈΡΠ½ΠΎ-ΠΊΠΎΠ½ΡΡΠ½ΠΊΡΠΈΠ²Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΡΠ΅ΡΠΎΠ·Π° (Π ΠΠ). ΠΡΡΠ²Π»Π΅Π½ΠΎ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²ΠΎ ΡΡ
Π΅ΠΌΡ Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΠΌΠΎΠ΄ΡΠ»ΡΡΠΎΡΠ° ΠΈ Π°Π½ΡΠΈΠΎΠΊΡΠΈΠ΄Π°Π½ΡΠ° Π² ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π΅Π½ΠΈΠΈ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π ΠΠ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠΉ ΡΡ
Π΅ΠΌΠΎΠΉ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠΎ ΡΠ°ΡΠΌΠ°ΠΊΠΎ-ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌ, Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ², ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ
Research action drug with immunomodulating and anti-oxidant effect in the complex therapy of experimental reproduction corneal conjunctival xerosis
The article shows the dynamics of clinical manifestations of corneal conjunctival xerosis and lacrimal fluid parameters of production on the experimental model of the experimental animals (rabbits) under general anesthesia, with playback corneal conjunctival xerosis the combined use derinat, emoxipine and accompanied by traditional therapy of postoperative transient corneal conjunctival xerosis. It was revealed that this scheme increases lacrimal glands function, as well as reduces the inflammatory manifestations, contributes to inflammatory complications and antioxidant activity of lacrimal fluid during therapy of corneal conjunctival xerosis.Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π° Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ° ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ ΡΠΎΠ³ΠΎΠ²ΠΈΡΠ½ΠΎ-ΠΊΠΎΠ½ΡΡΠ½ΠΊΡΠΈΠ²Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΡΠ΅ΡΠΎΠ·Π° ΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠΈ ΡΠ»Π΅Π·Π½ΠΎΠΉ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠΈ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΌΠΎΠ΄Π΅Π»ΠΈ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
(ΠΊΡΠΎΠ»ΠΈΠΊΠΎΠ²) Ρ Π²ΠΎΡΠΏΡΠΎΠΈΠ·Π²Π΅Π΄Π΅Π½Π½ΡΠΌ ΡΠΎΠ³ΠΎΠ²ΠΈΡΠ½ΠΎ-ΠΊΠΎΠ½ΡΡΠ½ΠΊΡΠΈΠ²Π°Π»ΡΠ½ΡΠΌ ΠΊΡΠ΅ΡΠΎΠ·ΠΎΠΌ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΠΎΠ±ΡΠ΅ΠΉ Π°Π½Π΅ΡΡΠ΅Π·ΠΈΠΈ ΠΏΡΠΈ ΡΠΎΡΠ΅ΡΠ°Π½Π½ΠΎΠΌ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ ΡΡΠΈΠ»Π»Π°Π²ΠΈΡΠ°, Π΄Π΅ΡΠΈΠ½Π°ΡΠ° ΠΈ ΡΠΌΠΎΠΊΡΠΈΠΏΠΈΠ½Π° Π² ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π΅Π½ΠΈΠΈ ΡΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠΎΠ³ΠΎΠ²ΠΈΡΠ½ΠΎ-ΠΊΠΎΠ½ΡΡΠ½ΠΊΡΠΈΠ²Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΡΠ΅ΡΠΎΠ·Π°. ΠΡΡΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΡΠΊΠ°Π·Π°Π½Π½Π°Ρ ΡΡ
Π΅ΠΌΠ° ΠΏΠΎΠ²ΡΡΠ°Π΅Ρ ΡΡΠ½ΠΊΡΠΈΡ ΡΠ»Π΅Π·ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ, Π°Π½ΡΠΈΠΎΠΊΡΠΈΠ΄Π°Π½ΡΠ½ΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ»Π΅Π·Π½ΠΎΠΉ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠΌΠ΅Π½ΡΡΠ°Π΅Ρ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ ΡΠΎΠ³ΠΎΠ²ΠΈΡΠ½ΠΎ-ΠΊΠΎΠ½ΡΡΠ½ΠΊΡΠΈΠ²Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΡΠ΅ΡΠΎΠ·Π°